Enhancing ADC Process Development Through Optimizing DAR Homogeneity, Controlling Impurities & Streamlining Unit Operations to Guarantee Product Quality & Support Regulatory Submissions

Underpinning successful ADC development is a robust, reproducible, and scalable process development strategy. From controlling impurities and optimizing conjugation yield to streamlining unit operations and executing technology transfer, it’s clear that the path to successful commercialization is enabled by a strong process development strategy.

That's why in 2025, the 3rd ADC Process Development Summit was the only meeting dedicated to the technical and strategic challenges of ADC process development. In an intimate setting, you joined 80+ experts from AstraZeneca, Merck, Gilead, Genentech, AbbVie, and more for two days of focused insights, real-world case studies, and peer-led discussion to revolutionize your antibody-drug conjugate manufacturing process.

This was your chance to uncover how to streamline purification strategies, scale up emerging conjugation approaches, define CQA-driven specifications, and scale up manufacturing while meeting evolving regulatory expectations. Whether you’ were supporting early-stage development or preparing for pivotal trials and BLA submissions, this was your opportunity to benchmark, troubleshoot, and advance your ADC process with confidence.